ImmunityBio in Focus as EU Decision Nears, Shares Hover Above Key Level
Published on 01/05/2026 at 08:53 | Redaktion boerse-global.de
ImmunityBio finished the first trading day of 2026 at $2.02, representing a 2.02% gain. The stock sits just above the $2.00 psychological threshold as investors await a ruling from the European Commission. Will an EU approval spark the anticipated push higher in the shares? The following points lay out the relevant facts.
- On December 12, 2025, the EMA’s CHMP issued a positive recommendation for conditional approval of ANKTIVA (nogapendekin alfa inbakicept) in combination with BCG for adults with BCG-unresponsive NMIBC CIS.
- This recommendation remains the principal fundamental driver. Typically, a formal EC decision follows a positive CHMP vote within roughly 67 days.
- The market has priced in a high likelihood of approval, yet short-interest rose about 23% in December, indicating prevailing skepticism among some market participants.
- At year-end, a financial publication named the stock a 2026 turnaround candidate, underscoring the EU decision as a key growth driver.
Financials, market outlook and potential impact
- ImmunityBio reported for November, on the third quarter, an EPS of -$0.07 per share versus an expected -$0.10, with revenue of $32.06 million. This suggests early commercial progress in the United States.
- An EU approval would accelerate commercial scaling and could trigger contractually defined milestone payments.
Technical viewpoint:
- Maintaining the $2.00 level is important for near-term direction.
- A move below this mark could prompt a retest of the 52-week low near $1.83.
- Conversely, a sustained break above $2.15 on rising volume would confirm a recovery in momentum.
Should investors sell immediately? Or is it worth buying ImmunityBio?
Timeline and broker perspective
Market guidance points to the European Commission’s decision window as late February to early March 2026. A formal approval would represent a meaningful catalyst, clarifying Europe’s revenue potential and scaling trajectory. Some research desks, including Jefferies, continue to rate the shares as a Buy with price targets positioned above the current level.
Ad
ImmunityBio Stock: Buy or Sell?! New ImmunityBio Analysis from January 5 delivers the answer:
The latest ImmunityBio figures speak for themselves: Urgent action needed for ImmunityBio investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from January 5.
ImmunityBio: Buy or sell? Read more here...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
